Abstract: The present invention relates i.a. to vaccines for combating Mycoplasma infection, to mycoplasmal L-?-glycerophosphate oxidase for use in such vaccines, to the use of mycoplasmal L-?-glycerophosphate oxidase for the manufacturing of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the discrimination of animals vaccinated with said vaccines and animals vaccinated with whole cell vaccines or animals suffering from field infection.

Abstract: The present invention relates to new attenuated M. bovis bacteria strains passaged at least 110 times. Moreover, the present invention also provides immunogenic compositions comprising live bacteria of any of those attenuated M. bovis bacteria strain, their manufacture and use for the treatment and prophylaxis of M. bovis infections and combinations with other veterinary vaccines or medicaments.

Abstract: The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a combination vaccine. The combination vaccine can be a whole or partial cell inactivated or modified live preparation.

Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.

Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably Carbopol, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as Pluronic®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.

Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.

Abstract: The present invention relates to the use of an immunogenic dose of immunogenic material of Mycoplasma hyopneumoniae and an immunogenic dose of live attenuated PRRS virus for the manufacture of a vaccine, and to a vaccine kit comprising such a vaccine.

Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.

Abstract: The present invention provides a Mycoplasma pneumoniae community acquired respiratory distress syndrome (CARDS) toxin, biologically active fragments/domains of the CARDS toxin, antibodies to the CARDS toxin and nucleic acids encoding the CARDS toxin. Also provided are methods of diagnosing, treating and/or preventing infection by Mycoplasma pneumoniae using the compositions provided herein.

Abstract: The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of M. bovis infections on milk production, weight gain and animal health. Methods of diagnosing, characterizing and treating M. bovis infections as specific biotypes are also disclosed. Vaccine compositions made in accordance with the invention may be either of the attenuated or inactivated variety. Vaccines may also include antigens from other pathogens so as to provide a protective immunogenic response to diseases other than those caused by M. bovis.

Abstract: The present invention relates to new attenuated M. bovis bacteria strains. Moreover, the present invention also provides immunogenic compositions comprising live bacteria of an of those attenuated M. bovis bacteria strain, their manufacture and use for the treatment and prophylaxis of M. bovis infections.

Abstract: Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating M. hyopneumoniae infection. Administration to an animal of one or two doses of an adjuvanted live avirulent M. hyopneumoniae composition disclosed herein is effective in providing immunity to the animal and protection from infection with a virulent strain of M. hyopneumoniae thereby reducing the severity of and/or preventing disease caused by one or more virulent strain of M. hyopneumoniae. Also provided are compositions, which further comprise one or more antigen such as, for example, one or more live bacteria, bacterin, toxoid, and/or virus and/or viral antigen. Exemplified are immunogenic compositions, comprising an adjuvanted live avirulent M.

Abstract: The present invention provides live, attenuated Mycoplasma gallisepticum bacteria that exhibit reduced expression of a protein identified as MGA_0621. In certain embodiments, the attenuated bacteria may additionally exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-type M. gallisepticum bacterium. Also provided are vaccines and vaccination methods involving the use of the live, attenuated M. gallisepticum bacteria, and methods for making live attenuated M. gallisepticum bacteria. An exemplary live, attenuated strain of M. gallisepticum is provided, designated MGx+47, which was shown by proteomics analysis to exhibit significantly reduced expression of MGA_0621, and was shown to be safe and effective when administered as a vaccine against M. gallisepticum infection in chickens.

Abstract: The present invention provides live, attenuated Mycoplasma bacteria that exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-type Mycoplasma bacterium of the same species. Also provided are vaccines and vaccination methods involving the use of the live, attenuated Mycoplasma bacteria, and methods for making live attenuated Mycoplasma bacteria.

Abstract: A novel chitinase, a polynucleotide encoding the same, a vector and a transformant comprising the polynucleotide, an antibody against the chitinase, and a screening method for screening a substance capable of modifying the chitinase, are disclosed. According to the chitinase, polynucleotide, or vector, it is possible, for example, to exterminate ticks, or to treat or prevent tick-borne infections such as piroplasmosis, Q fever, or viral encephalitis.

Abstract: A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating toxin, optionally comprising one or more amino acid additions, deletions or substitutions.

Abstract: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.

Abstract: The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect M. bovis infections on milk production, weight gain and animal health. Methods of diagnosing characterizing and treating M. bovis infections as specific biotypes are also disclosed. Vaccine compositions made in accordance with the invention may be either of the attenuated or inactivated variety. Vaccines may also include antigens from other pathogens so as to provide a protective immunogenic response to diseases other than those caused by M. bovis.

Abstract: The invention of novel, effective vaccines against Mycoplasma. bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of M. bovis infections on milk production, weight gain and animal health. Methods of diagnosing, characterizing and treating M. bovis infections as specific biotypes are also disclosed. Vaccine compositions made in accordance with the invention may be either of the attenuated or inactivated variety. Vaccines may also include antigens from other pathogens so as to provide a protective immunogenic response to diseases other than those caused by M. bovis.

Abstract: Mycoplasma hyopneumoniae polypeptides and nucleic acids, as well as nucleic acid expression vectors and host cells containing nucleic acid vectors are provided. In addition, compositions containing M. hyopneumoniae polypeptides and nucleic acids are provided for use in methods of treating swine to prevent enzootic pneumonia. Furthermore, the invention provides diagnostic tests for the detecting of M. hyopneumoniae infection in swine herds.

Abstract: The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of M. bovis infections on milk production, weight gain and animal health. Methods of diagnosing, characterizing and treating M. bovis infections as specific biotypes are also disclosed. Vaccine compositions made in accordance with the invention may be either of the attenuated or inactivated variety. Vaccines may also include antigens from other pathogens so as to provide a protective immunogenic response to diseases other than those caused by M. bovis.

Abstract: The present invention relates i.a. to vaccines for combating Mycoplasma infection, to mycoplasmal L-?-glycerophosphate oxidase for use in such vaccines, to the use of mycoplasmal L-?-glycerophosphate oxidase for the manufacturing of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the discrimination of animals vaccinated with said vaccines and animals vaccinated with whole cell vaccines or animals suffering from field infection.

Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.

Abstract: The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.

Abstract: The present invention provides a mycoplasma vaccine, its preparation and application thereof. The foregoing mycoplasma vaccine comprises inactivated Mycoplasma hyorhinis ATIT-7 only or the mixture of inactivated Mycoplasma hyorhinis ATIT-7 and inactivated Mycoplasma hyopneumoniae, which effectively prevents the infection of swine enzootic pneumonia in pigs.

Abstract: There is disclosed vaccines formulated for administration to the mucosa of the lungs of a mammal, and the use thereof in methods for prophylaxis or treatment of an infection by at least one pathogenic microorganism. The vaccines comprise a cellular fraction of the microorganism that is essentially free of particulate matter and includes polyvalent soluble antigen from the microorganism.

Abstract: The present invention provides a protective formulation that prevents virulent Mycoplasma gallisepticum infection in birds of the order Galliformes. The formulation comprises a protective amount of live MG strain K5054 or derivatives thereof in a pharmaceutically acceptable carrier. A vaccine that prevents virulent Mycoplasma gallisepticum infection in birds of the order Galliformes is also presented. Methods for administering the formulation and vaccine are also presented.

Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.

Abstract: The present invention relates to methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma bovis (M. bovis) by administering to the animal an effective amount of a Mycoplasma hyopneumoniae (M. hyo) vaccine. The M. hyo vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyo vaccine administered in accordance with the present invention can be synthesized or recombinantly produced.

Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.

Abstract: There is provided a DNA molecule derived from a prokaryotic cell in which at least one of the DNA regions encoding NXB (N is asparagine, X is any amino acid other than proline, and B is serine or threonine) has been modified so that no N-glycosylation occurs during the expression in a eukaryotic cell, and since the DNA molecule has been modified at the N-glycosylation site, it produces a non-N-glycosylated protein, which thereby exhibits a high immunogenicity when, for example, it is allowed to produce, in a eukaryotic cell, an antigen protein derived from a prokaryotic cell.

Abstract: The present invention relates to methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma hyopneumoniae (M. hyo) by administering to the animal at approximately three (3) to ten (10) days of age, a single dose of an effective amount of a M. hyo vaccine. The M. hyo vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyo vaccine administered in accordance with the present invention can be synthesized or recombinantly produced.

Abstract: A strain of Mycoplasma which is a causative agent of bovine pneumonias, which has been inactivated by treatment with an agent, which disrupts cel membranes such as saponin, is described. Preferably, the strain is Mycoplasma bovis or Mycoplasma mycoides subsp. mycoides SC. These strains can be used as vaccines. Veterinary compositions, methods of preparing these and their use in prophylaxis is also described and claimed.

Abstract: The present invention involves a method and an immuno-analytical device for the rapid and simultaneous detection of multiple micro-organisms in the biological fluids from milk-producing animals suffering from mastitis. This method is based on a lateral flow immuno-assay technique performed to detect antigens specific for multiple infectious agents which are known to cause and/or be encountered in cases of mastitis. Mastitis is an inflammatory condition affecting the udders of milk-producing animals as a result of microbial infections.

Abstract: This invention relates to recA mutant mycobacteria, particularly mutants of mycobacterial species which are members of the Mycobacterium tuberculosis complex, such as M. bovis BCG and M. tuberculosis. These mutant mycobacteria are useful as immunotherapteutic agents and vaccines for the treatment of a range of disorders, including tuberculosis.

Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.

Abstract: A biologically-active material comprising a live virus or mycoplasma is preserved by a method of desiccation, without lyophilisation, in a matrix of glassy trehalose having a residual moisture content of not greater than 2%. The method comprises two vacuum drying stages. In a cycle time much shorter than a typical freeze drying process a virus or mycoplasma can be preserved to provide a material that can be rehydrated to give a vaccine having potency.

Abstract: The present invention provides a reproducible M. bovis challenge model and methods for reliably inducing and establishing a disease or disorder caused by infection with M. bovis by administering to an animal an effective amount of a M. bovis culture. The challenge culture of the present invention is administered in an amount sufficient to elicit M. bovis specific cellular or humoral immune responses. The M. bovis challenge model in accordance with the present invention can be used to evaluate the efficacy of potential vaccines.

Abstract: Novel mycobacterial sulfation pathway proteins and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting growth and/or virulence of a pathogenic mycobacterium, and methods of treating disease conditions associated with a pathogenic mycobacterium, particularly by administering an inhibitor of a mycobacterial sulfation pathway protein. The present invention further provides genetically modified mycobacteria having a defect in a sulfation pathway enzyme gene; and immunogenic compositions that include such genetically modified mycobacteria.

Abstract: The present invention provides a live temperature-sensitive vaccine for Mycoplasma hyopneumoniae. The present invention also provides methods of vaccinating a swine against colonization or infection of Mycoplasma hyopneumoniae.

Abstract: A mutated mycobacterium selected from the class consisting of mutated M. bovis-BCG, mutated M. tuberculosis, and mutated M. leprae. The mutation of M. bovis-BCG, M. tubeiculosis, or M. leprae is preferably effected through an insertional mutation of a mycobacterial gene. The insertional mutagenesis may be effected, for example, through illegitimate recombination or by a mycobacterial transposon. Such mutated mycobacteria may then be transformed with an expression vector(s) containing a complement gene to the gene which is mutated, and preferably also including a heterologous gene.

Abstract: The present invention provides a bacterin comprising at least two virulent Mycoplasma bovis isolates of differing biotypes, in an amount sufficient to immunize a calf or cow against infection by Mycoplasma bovis, an adjuvant, and a pharmaceutically acceptable carrier. Further provided is a method of producing the bacterin of the present invention. Finally, the present invention also provides a method of immunizing a calf or cow against Mycoplasma bovis infection, especially infection associated with BRD, comprising administering to the calf or cow a dose of a bacterin made according to the present invention in an amount effective to elicit a protective response in the animal, as evidenced by a decrease in the mortality and morbidity associated with natural infection.

Abstract: The invention features fusion agents such as fusion proteins that are useful for the treatment of and prevention from diseases that are susceptible to the effects of cellular (Th1 type) immune responses. Also encompassed by the invention are nucleic acids encoding the fusion proteins of the invention, vectors containing the nucleic acids, and cells containing the vectors. The invention includes methods of making and using the fusion agents of the invention.

Abstract: The invention relates to immunomodulatory effective microbiological compositions, to methods for the production thereof and to their use. The inventive microbiological immuno modulators are suited for use in active and passive immunization. The inventive compositions are primarily used as homeopathic medications in the areas of cardiac and circulatory disorders, hypertension or allergic ailments. The immunomodulatory effective microbiological compositions are comprised of equal parts of antigen and antitoxin suspensions and are potentiated using a potentiating solution.

Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.

Abstract: Methods and compositions for the treatment and prevention of infectious diseases are provided. In particular, efficient vaccines comprising genetically modified pathogens are provided. The vaccines generally comprise mycobacterial mutants having modified protein production capabilities. In one embodiment, the mutants overexpress heat shock protein. In a specific embodiment, the mycobacterial mutant overexpresses heat shock proteins 60 and/or 70. Also provided are modified BCG vaccines capable of overexpressing heat shock proteins 60 and/or 70.

Abstract: The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis, BCG, engineered to express a MUC1 polypeptide and human interleukin-2 for use in cancer immunotherapy.

Abstract: The present invention provides a bacterin comprising at least two virulent Mycoplasma bovis isolates of differing biotypes, in an amount sufficient to immunize a calf or cow against infection by Mycoplasma bovis, an adjuvant, and a pharmaceutically acceptable carrier. Further provided is a method of producing the bacterin of the present invention. Finally, the present invention also provides a method of immunizing a calf or cow against Mycoplasma bovis infection, especially infection associated with BRD, comprising administering to the calf or cow a dose of a bacterin made according to the present invention in an amount effective to elicit a protective response in the animal, as evidenced by a decrease in the mortality and morbidity associated with natural infection.

Abstract: Vaccines based on combinations of majorly abundant extracellular products of pathogens and methods for their use and production are presented. The most prevalent or majorly abundant extracellular products of a target pathogen are selected irrespective of their absolute molecular immunogenicity and used as vaccines to stimulate a protective immune response in mammalian hosts against subsequent infection by the target pathogen. The majorly abundant extracellular products may be characterized and distinguished by their respective N-terminal amino acid sequences. As the vaccines may comprise different combinations of the extracellular products, a broad range effective immunotherapeutic compositions are provided by the present invention. In addition to other infectious agents, the vaccines so produced can be used to stimulate an effective immune response against intracellular pathogens and in particular Mycobacterium tuberculosis.

Abstract: The invention relates to a method for making an inactivated vaccine of Mycoplasma hyopneumoniae by inactivating the bacteria with Thimerosal. The resulting bacterin is mixed with an adjuvant of aluminum hydroxide and DEAE dextran and injected into pigs. The resulting bacterin and adjuvant mixture can also be mixed with other bacteria such as Bordetella and Pasteurella, for further adjuvant effect. Protective immunity against mycoplasmal pneumonia is elicited in swine using these vaccines.